Anecortave (rINN) /ænəˈkɔrteɪv/ is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus which can be derived from cortisol it possesses little glucocorticoid activity. It will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.
This page contains content from the copyrighted Wikipedia article "Anecortave"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
